Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Annals of Neurology

Volumn 54, Issue 1, 2003, Pages 93-101

  Whone, Alan L ^a   Watts, Ray L ^b   Stoessl, A Jon ^c   Davis, Margaret ^b   Reske, Sven ^d   Nahmias, Claude ^e   Lang, Anthony E ^f   Rascol, Olivier ^g   Ribeiro, Maria J ^h   Remy, Philippe ^h   Poewe, Werner H ⁱ   Hauser, Robert A ^j   Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ULM   (Germany)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h DIF   (France)

ⁱ UNIVERSITY OF INNSBRUCK   (Austria)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPA; DOPAMINE; FLUORINE 18; LEVODOPA; ROPINIROLE; SINEMET LS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPROTECTION; OUTCOMES RESEARCH; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SUBSTANTIA NIGRA;

EID: 0037785449     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10609     Document Type: Article

References (30)

1. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
3. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716.
4. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44(3 suppl 1):S72-S84.
5. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann N Y Acad Sci 2000;899:112-120.
6. Barzilai A, Melamed E, Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease. Cell Mol Neurobiol 2001;21:215-235.
7. Martignoni E, Blandini F, Godi L, et al. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. Free Radic Biol Med 1999;27:428-437.
8. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999;838:51-59.
9. Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
10. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
11. Schulzer M, Mak E, Calne DB. The antiparkinsonian efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
12. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-138.
13. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in man studied with positron emission tomography. Ann Neurol 1989;26:535-542.
14. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
15. 18F]dopa-PET study. Brain 1999;122:1637-1650.
16. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
17. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
18. 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 1996;136:169-173.
19. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
20. 18F]dopa PET. J Neurol. Neurosurg Psychiatry 1998;64:314-319.
21. 18F-dopa PET findings. Mov Disord 2000;5(suppl 2):S308.
22. 18Fdopa PET study. J Neural Transm 2002;109:1433-1443.
23. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
24. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
25. Marek K, Seibyl J, Shoulson I, et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
26. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
27. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapping 1995;2:189-210.
28. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
29. 11C-raclopride PET studies. Neurology 1999;52:932-937.
30. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002;43:201-207.